NAD+ — Evidence, Legality & Programs
NAD+ therapy: current evidence base, legality, safety and telehealth availability.
Evidence-based answer
NAD+ therapy: current evidence base, legality, safety and telehealth availability.
Regulatory status: NAD+ injections and infusions marketed for anti-aging, energy or cognitive enhancement are not FDA approved for those uses. Oral precursors and intravenous NAD+ are different interventions.
How it works
NAD is a cellular cofactor involved in redox reactions, mitochondrial metabolism and signaling. Restoring a biomarker does not automatically improve patient-centered outcomes.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
Human outcome evidence for intravenous or injectable NAD+ wellness programs is limited. Studies of nicotinamide riboside or NMN cannot prove the efficacy of injected NAD+.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| Evidence grade | Varies by molecule | Exact product and route required | See primary sources | Do not extrapolate animal or mechanism data to human outcomes |
Clinical-use framework
There is no FDA-approved anti-aging injection schedule. Clinic protocols vary and are not validated by a standardized pivotal trial program.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Infusion-related nausea, flushing, chest discomfort and cramping have been reported, while compounded injectable quality and sterility add separate risk. Long-term outcome data are limited.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is NAD+ therapy FDA approved?
NAD+ injections and infusions marketed for anti-aging, energy or cognitive enhancement are not FDA approved for those uses. Oral precursors and intravenous NAD+ are different interventions.
What is the strongest evidence for NAD+ therapy?
Human outcome evidence for intravenous or injectable NAD+ wellness programs is limited. Studies of nicotinamide riboside or NMN cannot prove the efficacy of injected NAD+.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- FDA human drug compounding Primary clinical or regulatory source
- NAD metabolism review Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.